CVS Health (CVS) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $2.58
- Estimate
- $1.85
- Surprise
- +39.4%
- Revenue (period 2026-06-30)
- $106.10B
- Score today
- 6.1/10
Revenue source: xbrl.
How the report landed
CVS Health (CVS) beat the $1.85 estimate with adjusted EPS of $2.58 — a large 39.4% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates CVS Sell at 6.1/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +39.4% surprise compares with a +20.8% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Quality below floor (3.4 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $86.43
- Price target
- $104.18
- Stop
- $82.49
- Upside to target
- +20.5%
- Reward-to-risk
- 4.1:1
The stock trades at 22.7× trailing but 10.1× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
CVS at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Healthcare Plans
- Market cap
- $110.54B
- P/E (fwd)
- 10.1
- P/E (ttm)
- 22.7
- 52-week range
- $69.51–$110.68
- Off 52-week high
- 21.9%
- RSI (14)
- 35
- Volume vs avg
- 1.27×
- Score today
- 6.1/10